[1] | Ministry of Health, Malaysia. Clinical Practice Guidelines (CPG). Management of Type 2 Diabetes Mellitus (T2DM). 5th ed. 2015 Dec. pp 57-58. |
[2] | Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. 2014; 5(2): 355–66. |
[3] | NKF. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. Elsevier Inc. 2012; 60(5): 850–86. |
[4] | Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3(1): 1–150. |
[5] | Ricks J, Molnar MZ, Kovesdy CP, Shah A, Nissenson AR, Williams M, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes. 2012; 61: 708–15. |
[6] | Ramirez SP, McCullough KP, Thumma JR, Nelson RG, Morgenstern H, Gillespie BW, et al. Hemoglobin A(1c) levels and mortality in the diabetic hemodialysis population: findings from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Diabetes Care. 2012; 35: 2527–32. |
[7] | Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic Kidney Disease: A Report from an ADA Consensus Conference. Diabetes Care. 2014; 37(10): 2864–83. |
[8] | Ahmed SS, Ali MZ, Laila TR, Begum HA & Ali TMM. Review article: Update on Pharmacotherapy for Type 2 Diabetes. KYAMC Journal. 2012 Jun; 3(1): 251-62. |
[9] | Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995 Nov; 35(11): 1094-102. |
[10] | Salpeter SR, Greyber E, Pasternak GA, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Sys Rev. 2010(4): CD002967. |
[11] | U.S. Department of Health and Human Services. U.S. Food and Drug Administration: FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [Internet]. Available from http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed 15 October 2016. |
[12] | American Diabetes Association. Diabetes Care. 2018 Jan; 41 (Supplement 1): S73-S85. https://doi.org/10.2337/dc18-S008. |
[13] | Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312: 2668–75. doi: 10.1001/jama.2014.15298. |
[14] | Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol. 2008; 40: 411–17. doi: 10.1007/s11255-008-9371-6. |
[15] | Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016; 164(11): 740–51. |
[16] | Holstein A, Plaschke A, Hammer C, Ptak M, Kuhn J, Kratzsch C, et al. Hormonal counter-regulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. Eur J Clin Pharmacol. 2003; 59: 747–54. |
[17] | Zanchi A, Lehmann R, Philippe J. Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly. 2012; 142: w13629. doi: 10.4414/smw.2012.13629. |
[18] | Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial. 2004; 17(5): 365–70. |
[19] | Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia. 1973; 9(Suppl 1):331–38. |
[20] | Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients with Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency. Diabetes Care. 2013; 36(5): 1067-73. doi: 10.2337/dc12-1365. |
[21] | Alsahli M, Gerich JE. Hypoglycemia in Patients with Diabetes and Renal Disease. J Clin Med. 2015; 4(5): 948-64. |
[22] | Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996; 39(12): 1617-24. |
[23] | Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, et al. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol. 2003; 60(2): 90–95. |
[24] | Hasslacher C, Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003; 26(3): 886-91. |
[25] | Abe M, Okada K, Soma M. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Curr Drug Metab. 2011 Jan; 12(1): 57-69. |
[26] | Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193–203. |
[27] | Williams ME, Garg R. Glycemic management in ESRD and earlier stages of CKD. Am J Kidney Dis. 2014; 63(2 Suppl 2): S22–38. doi: 10.1053/j.ajkd.2013.10.049. |
[28] | Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis. 2007; 50(5): 865–79. |
[29] | Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007; 30: 1862–4. |
[30] | Eligar VS, Bain SC. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug Des Devel Ther. 2013; 7: 893–903. |
[31] | Nowicki M1, Rychlik I, Haller H, Warren ML, Suchower L G-NI. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13(6): 523–32. |
[32] | Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010; 70(15): 2051–72. |
[33] | Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011; 13: 939–46. |
[34] | von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovasc Diabetol. 2013; 12: 60. Published online 2013 Apr 9. doi:10.1186/1475-2840-12-60. |
[35] | Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013; 6: 161–70. |
[36] | Cooper ME, Perkovic V, McGill JB, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis. 2015; 66: 441–49. |
[37] | Kim YG, Byun J, Yoon D, Jeon JY, Han SJ, Kim DJ, et al. Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study. J Diabetes Res. 2016; Published online 2016 Dec 29. doi: 10.1155/2016/1423191. |
[38] | Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011; 58: 69–73. |
[39] | Sakata K, Hayakawa M, Yano Y, Tamaki N, Yokota N, Eto T, et al. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE): receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab Res Rev. 2013; 29: 624–30. |
[40] | Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013; 36: 3460–68. |
[41] | Xia C, Goud A, D'Souza J, Dahagam C, Rao X, Rajagopalan S, Zhong J. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev. 2017 May; 22(3): 299-304. doi: 10.1007/s10741-017-9617-4. |
[42] | Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol. 2012; 52: 457–63. |
[43] | Brunton SA. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract. 2015; 69(10): 1071-87. |
[44] | Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015 Mar; 12(2): 90-100. doi: 10.1177/1479164114559852. |
[45] | Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015; 38: 1687-93. |
[46] | Rosenstock J, Ferrannini E. Euglycaemic Diabetic Ketoacidosis: A Predictable, Detectable and Preventable Safety Concern with SGLT2 inhibitors. Diabetes Care. 2015; 38: 1638-42. |
[47] | US Food and Drug Administration. FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana, Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Safety Announcement 2015; http://www.fda.gov/Drugs/DrugSafety/ucm461449.htm. |
[48] | Freeman JS. Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors. Postgrad Med. 2013 May; 125(3): 214-26. |
[49] | Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin North Am. 2015; 99(1): 87-106. doi: 10.1016/j.mcna.2014.08.012. |
[50] | Vlotides G, Mertens PR. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol Dial Transplant. 2015 Aug; 30(8): 1272-76. |
[51] | Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1): 64-74. doi: 10.1159/000364909. |
[52] | Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587–97. |
[53] | Wanner C, Inzucchi SE, Lachin JM, Lachin JM, Fitchett D, von Eynatten M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323–34. doi: 10.1056/NEJMoa1515920. |
[54] | Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017 Jan; 28(1): 368-75. doi: 10.1681/ASN.2016030278. |
[55] | Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al.; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–57. |
[56] | Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382: 941–50. |
[57] | Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014; 85: 962–971. |
[58] | Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–28. |
[59] | Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44: 375–93. |
[60] | Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013; 159(4): 262–74. |
[61] | US Food and Drug Administration. FDA News Release on Dec 02, 2016. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm531517.htm. |